Galena Biopharma. Where Will IT Go Next ?

Galena Biopharma which, is posted on Earningswhisper.com stated
that the 4th Quarter Earnings report ending December 2013 has a release Date of 3/12/2014 after the market close but not confirmed. It shows that the lookout from visitor's sentiment is a Strong Buy and Analysts Recommendation is also a Strong Buy with a target price of $8.50.

On Yahoo Finance,

Galena Biopharma has a Recommendation of a 1.9 with 1.0 as a strong buy down to 5.0 as a sell.
With 9 Brokers showing a price target summary from a low target price of $4.00 and a high target of $12.00.

On December 31, 2013 the price on Gale moved to high price of $5.30 per share on increase Volume. With the volume hitting a high for 2014 of 25,420,800 on January 8, 2014 and high price for that day of $6.84. This to me would be due to day traders moving in. The gap from the high price to the low price was $1.34.

After, some insiders selling on 1/17/2014 and 1/22/2014 from STOCK OPTIONS we have people who are now shorting the stock. They can get with there broker to sell shares first at higher price and buy them back to "cover" at a lower price on the same day.

As of 1/24/2014
Galena stock ownership is.
1.2% Brokerage Firms
16.1% Investments Managers
.6 % Strategic Entities
82.1 % Non- Institutional

After, what I think where some misleading articles at Seeking Alpha they used it to promote a different stock. As anyone knows that have traded Healthcare or Biotechnology & Drug Company's they all come with a very high risk , but if they hit the rewards are very high. Now, for a short look at where Galena is now;

ANNUAL REPORT 2012
Mark j. Ahn, Ph. D.
President and chief executive officer

Wrote a letter to shareholders in the Annual report from 2012.
Here are some high points from that letter.

THAT GALENA BIOPHARMA HAS MADE TREMENDIUS PROGRESS AS WE TRANSFRORMED FROM A PRECLINICAL RESEARCH COMPANY IN EARLY 2011 INTO AN ONCOLOGY COMPANY WITH A DIVERSIFIED, LATE STAGE PRODUCT PIPELINE OF NOVEL CANCER IMMUNOTHERAPIES AT BLOCKBUSTER MARKETS IN 2012. WITH THE ACQUISITION OF AN F.D.A. - APPROVED PRODUCT TO START 2013, I AM MORE EXCITED THAN EVER ABOUT OUR PROSPECTS AS WE FURTHER ACCELERATE INTO A COMMERCIAL COMPANY. OUR MISSION AT GALENA REMAINS: DEVELOPING TARGETED ONCOLOGY TREATMENTS THAT ADDRESS MAJOR UNMET MEDICAL NEEDS TO ADVANCE CANCER CARE.

IN MARCH 2013 GALENA ACQUIRED Abstral (FENTANYL) SUBLINGUAL TABLETS FOR SALE AND DISTRIBUTION IN THE UNITED STATES FROM SWEDEN- BASED OREXO AB. MARK Said WE BELIEVE ABSTRAL CAN SIGNIFICANTLY ADVANCE CARE FOR THE 40 - 80 % OF CANCER PATIENTS WHO EXPERIENCE BREAKTHROUGH PAIN.

Abstral is approved by the U.S. food and drug Administration (FDA) for treatment of breakthrough cancer pain. In Europe it is marketed by ProStrakan/Kyowa Hakko Kirin where it was the market leader in 2012. Galena expected to launch Abstral into the $ 400 million U.S. Market for Transmucosal immediate- release fentanyl (TIRF) products in the fourth quarter of 2013.

From a financial perspective the acquirement of Abstral will produce near -term revenues. Which will reduce the overall cash burn between now and the launch of Neu Vax. The revenue will allow Galena to build more relationships with future prescribers of NeuVax. This should include oncologists who are currently treating patients with advanced breast cancer and other solid tumors for breakthrough cancer pain.
Galena Biopharma Inc has made significant corporate progress and with revenues expected in 2014.

To me Galena looks to be inline on its mission statement of transforming itself into a commercial BIOPHARMA company.

Galena so far in 2014 has accomplished the following:

On January 7 Enrolled in the first patient in a phase 2 study of its Fbp vaccine GALE- 301 in HlA-A2 positive patients. The Phase 2 trial for GALE-301, which is a folate binding protein with potential use in conjunction with an adjuvant to prevent recurrences in high-risk, endometrial and ovarian cancer patients.

On January 13 2014 the company buys Mills Pharmaceuticals. Giving Gale rights to Gale-401. Total sales from the drug are estimated to be worth up to $200 million per annum

On January 14 2014 stuck a strategic development and commercialization deal with DR. Ready's Laboratories (RDY) for NeuVax in India.
Galena receiving development and sales milestones as well as double-digit royalties on net sales.

On January 14 2014 Roth Capital`s change target price to $12 from $11. They had just raised it from $7 to $11 on January 13 2014

On January 21 2014 Price target boosted to $9.00 from $ 3.50 by analysts at Needham & Company, they upgraded GALE stock from Underperform to Buy rating.

Galena is in the phase 3 clinical trial for NeuVax and the clinical trail for Folate protein. If the trails of Neuvax are successful the sky is the limit.

I'm long on Galena and feel that the closing price on Friday January 24,2014 of $5.70 is a strong buy rating.

Disclosure: I am long GALE, .